We have collected information about Nanoparticle-Based Delivery Of Rnai Therapeutics Progress And Challenges for you. Follow the links to find out details on Nanoparticle-Based Delivery Of Rnai Therapeutics Progress And Challenges.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649006/
Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy.Author: Jiehua Zhou, Ka To Shum, John C. Burnett, John J. Rossi
https://www.mdpi.com/1424-8247/6/1/85/htm
Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy.Author: Jiehua Zhou, Ka To Shum, John C. Burnett, John J. Rossi
https://www.researchgate.net/publication/236693091_Nanoparticle-Based_Delivery_of_RNAi_Therapeutics_Progress_and_Challenges
Jan 16, 2013 · Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges Jiehua Zhou 1,† , Ka-To Shum 1,† , John C. Burnett 1 and John J. Rossi 1,2, *
https://www.ncbi.nlm.nih.gov/pubmed/22915840
The main aims of this review are: to explain the siRNA mechanism with regard to potential applications in siRNA-based cancer therapy; to discuss the possible usefulness of nanoparticle-based delivery of certain molecules for overcoming present therapeutic limitations; to review the ongoing relevant clinical research with its pitfalls and promises; and to evaluate critically future perspectives and challenges in siRNA-based cancer therapy.Author: Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Enzo Di Fabrizio, Elisabetta Ferretti, Silverio T...
https://link.springer.com/article/10.1208/s12248-018-0267-9
Oct 10, 2018 · Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics. Abstract. The recent progress in harnessing the efficient and precise method of DNA editing provided by CRISPR/Cas9 is one of the most promising major advances in the field of gene therapy.Author: Brittany E. Givens, Youssef W. Naguib, Youssef W. Naguib, Sean M. Geary, Eric J. Devor, Aliasger K. ...
https://www.hindawi.com/journals/bmri/2013/782041/
RNA interference (RNAi) is a gene regulation mechanism initiated by RNA molecules that enables sequence-specific gene silencing by promoting degradation of specific mRNAs. Molecular therapy using small interfering RNA (siRNA) has shown great therapeutic potential for diseases caused by abnormal gene overexpression or mutation.Author: Jong-Min Lee, Tae-Jong Yoon, Young-Seok Cho
https://www.nature.com/articles/s41467-018-03705-y
Apr 12, 2018 · Here, the authors survey the challenge, progress and opportunities towards targeted delivery of cancer therapeutics. Targeted delivery approaches for cancer therapeutics have shown a …Author: Daniel Rosenblum, Nitin Joshi, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Jeffrey M. Karp, Dan Peer
https://www.nature.com/articles/nbt.3078
Nov 17, 2014 · Neutralizing the RNA phosphodiester backbone enables delivery of siRNA across cell membranes. RNA interference (RNAi) has great potential to treat human disease1,2,3.Author: Bryan R Meade, Khirud Gogoi, Alexander S Hamil, Caroline Palm-Apergi, Arjen van den Berg, Jonathan C...
https://www.hindawi.com/journals/jnm/2013/863951/
Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges. 1Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. 2Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.Author: Anish Babu, Amanda K. Templeton, Anupama Munshi, Rajagopal Ramesh
https://www.sciencedirect.com/science/article/pii/S2211383513000610
An alternative approach to the treatment of coronary artery disease is the delivery of potent angiogenic factors to stimulate new vessel growth using gene transfer109. With increased understanding of the mechanism of endogenous RNAi, the next few years will bring new applications of this exciting therapeutic approach.Author: Kun Gao, Leaf Huang
Searching for Nanoparticle-Based Delivery Of Rnai Therapeutics Progress And Challenges?
You can just click the links above. The data is collected for you.
